The Moderna Vaccine IndexThese companies are selected for composition "Moderna Vaccine" because
1.developed the vaccine
2.suppliers
3.distribution chain
Weights are calculated by relative market cap.
Next report date
Report period
Q1 2024
EPS estimate
—
Revenue estimate
153.70 MEUR
3.20EUR
170.34 MEUR
829.51 MEUR
17.95 M
About LABORATORIOS FARMACEUTICOS ROVI S.A.
Sector
CEO
Juan López-Belmonte Encina
Headquarters
Madrid
Website
Employees (FY)
2.11 K
Founded
1946
ISIN
ES0157261019
FIGI
BBG00JHVW8P1
Laboratorios Farmaceúticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. It operates through the following business segments: Manufacturing, Marketing, and Other. The Manufacturing segment obtains its income from service contracts that relate to the finalization of the pharmaceutical product production process for external entities and the manufacture of products to be subsequently marketed by other group companies. The Marketing segment purchases and sells pharmaceutical products. The Other segment includes other services, research, and development activities that are not significant for the group. The company was founded on December 21, 1946 and is headquartered in Madrid, Spain.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 0ILL is 84.35 EUR — it has decreased by 0.53% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange LABORATORIOS FARMACEUTOCOS ROVI SA EUR0.06 stocks are traded under the ticker 0ILL.
LABORATORIOS FARMACEUTOCOS ROVI SA EUR0.06 is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
0ILL stock is 3.34% volatile and has beta coefficient of 0.32. Check out the list of the most volatile stocks — is LABORATORIOS FARMACEUTOCOS ROVI SA EUR0.06 there?
0ILL earnings for the last quarter are 0.15 EUR per share, whereas the estimation was 0.11 EUR resulting in a 36.36% surprise. The estimated earnings for the next quarter are 0.61 EUR per share. See more details about LABORATORIOS FARMACEUTOCOS ROVI SA EUR0.06 earnings.
LABORATORIOS FARMACEUTOCOS ROVI SA EUR0.06 revenue for the last quarter amounts to 214.05 M EUR despite the estimated figure of 210.56 M EUR. In the next quarter revenue is expected to reach 223.60 M EUR.
Yes, you can track LABORATORIOS FARMACEUTOCOS ROVI SA EUR0.06 financials in yearly and quarterly reports right on TradingView.
0ILL stock has risen by 7.46% compared to the previous week, the month change is a 4.66% rise, over the last year LABORATORIOS FARMACEUTOCOS ROVI SA EUR0.06 has showed a 107.46% increase.
0ILL net income for the last quarter is 51.51 M EUR, while the quarter before that showed 52.18 M EUR of net income which accounts for −1.29% change. Track more LABORATORIOS FARMACEUTOCOS ROVI SA EUR0.06 financial stats to get the full picture.
Today LABORATORIOS FARMACEUTOCOS ROVI SA EUR0.06 has the market capitalization of 4.40 B, it has decreased by 2.69% over the last week.
Yes, 0ILL dividends are paid annually. The last dividend per share was 1.05 EUR. As of today, Dividend Yield (TTM)% is 1.23%. Tracking LABORATORIOS FARMACEUTOCOS ROVI SA EUR0.06 dividends might help you take more informed decisions.
Like other stocks, 0ILL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade LABORATORIOS FARMACEUTOCOS ROVI SA EUR0.06 stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 28, 2024, the company has 2.11 K employees. See our rating of the largest employees — is LABORATORIOS FARMACEUTOCOS ROVI SA EUR0.06 on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So LABORATORIOS FARMACEUTOCOS ROVI SA EUR0.06 technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating LABORATORIOS FARMACEUTOCOS ROVI SA EUR0.06 stock shows the buy signal. See more of LABORATORIOS FARMACEUTOCOS ROVI SA EUR0.06 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on LABORATORIOS FARMACEUTOCOS ROVI SA EUR0.06 future price: according to them, 0ILL price has a max estimate of 93.00 EUR and a min estimate of 60.00 EUR. Read a more detailed LABORATORIOS FARMACEUTOCOS ROVI SA EUR0.06 forecast: see what analysts think of LABORATORIOS FARMACEUTOCOS ROVI SA EUR0.06 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. LABORATORIOS FARMACEUTOCOS ROVI SA EUR0.06 EBITDA is 243.80 M EUR, and current EBITDA margin is 29.39%. See more stats in LABORATORIOS FARMACEUTOCOS ROVI SA EUR0.06 financial statements.